Acesso livre
Acesso livre

Destaques

Estudo de caso-controle | Risco de COVID longa associado com variantes Delta vs. Ômicron do SARS-CoV-2.

21 Jun, 2022 | 13:06h

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 – The Lancet

Comunicado de imprensa: Long COVID risk less during Omicron compared to Delta, study finds – King’s College London

Comentários:

Expert reaction to study looking at long COVID prevalence associated with delta versus omicron variants of SARS-CoV-2 – Science Media Centre

Omicron less likely to lead to long COVID, study finds – CIDRAP

Covid-19: Long covid risk is lower with omicron than delta, researchers find – The BMJ

 

Comentário no Twitter

 


Estudo de consenso | Estabelecido de desfechos para a condição pós-COVID-19 para uso na prática clínica e em pesquisas.

21 Jun, 2022 | 13:05h

A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study – The Lancet Respiratory Medicine

Comunicado de imprensa: Key outcomes of Long COVID identified in international consensus study – King’s College London

Comentário convidado: Post-COVID-19 condition in children: a COS is urgently needed – The Lancet Respiratory Medicine

 

Comentário no Twitter

 


Dicas para Covid longa: cientistas se esforçam para desvendar o que determina os sintomas incapacitantes.

21 Jun, 2022 | 13:03h

Clues To Long Covid – Science


[Preprint] Estudo randomizado aberto | Baricitinibe é não inferior ao tocilizumabe em pacientes internados com COVID-19 grave.

21 Jun, 2022 | 13:01h

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Conteúdos relacionados:

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

 


Diretriz científica AHA | Revascularização para doença renovascular.

19 Jun, 2022 | 17:24h

Revascularization for Renovascular Disease: A Scientific Statement From the American Heart Association – Hypertension

Principais tópicos a saber: Revascularization for Renovascular Disease – American Heart Association

Comentário: When is Renovascular Hypertension Amenable to Revascularization – American Heart Association


Estudo randomizado | Uso rotineiro de cateter urinário intraoperatório não reduz o risco de retenção urinária pós-operatória após reparo laparoscópico de hérnia inguinal.

19 Jun, 2022 | 17:22h

Effect of Intraoperative Urinary Catheter Use on Postoperative Urinary Retention After Laparoscopic Inguinal Hernia Repair: A Randomized Clinical Trial – JAMA Surgery (gratuito por tempo limitado)

Comentários: Urinary Catheters for Inguinal Hernia Repair—The Challenges of Deimplementation of Routine Procedures – JAMA Surgery (gratuito por tempo limitado)

Intraoperative Catheter Disappoints for Urinary Retention After Hernia Repair – MedPage Today (necessário cadastro gratuito)

Entrevista com os autores: Intraoperative Urinary Catheter Use and Urinary Retention After Laparoscopic Inguinal Hernia Repair – JAMA

 

Comentário no Twitter

 


Estudo de caso controle com teste negativo | Efeitos de infecção prévia e vacinação sobre infecções sintomáticas pela variante Ômicron.

19 Jun, 2022 | 17:20h

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections – New England Journal of Medicine

Comentário: Qatar Omicron-wave study shows slow decline of natural immunity, rapid decline of vaccine immunity – Weill Cornell Medicine

Conteúdos relacionados:

Hybrid immunity: a combination of vaccination and prior infection probably offers the best protection against COVID – The Conversation

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Two new studies show vaccination provides additional protection after Covid-19 infection.

 

Comentário no Twitter

 


Conselho do FDA é favorável às vacinas contra COVID-19 para crianças mais novas.

19 Jun, 2022 | 17:18h

FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

Ver também: FDA advisers endorse 1st COVID-19 shots for kids under 5 – Associated Press


Período de incubação da varíola dos macacos: estimativas da Holanda.

19 Jun, 2022 | 17:16h

Comunicado de imprensa: Incubation period for monkeypox: Estimates from the Netherlands – European Centre for Disease Prevention and Control (ECDC)

Estudo original: Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022 – Eurosurveillance

 

Comentário no Twitter (fio – clique para saber mais)

 


Diretriz NICE | Redução das infecções sexualmente transmissíveis.

19 Jun, 2022 | 17:05h

Reducing sexually transmitted infections – National Institute for Health and Care Excellence


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.